Company intelligence / Profile preview

Crescent Group

Waltham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Crescent Biopharma is developing a tetravalent bispecific PD-1 x VEGF monoclonal antibody (CR-001) for solid tumors, with IND planned Q4 2025 and proof-of-concept Phase 1 trial data expected in 2026. Two novel ADCs (CR-002, CR-003) with topoisomerase inhibitor payloads are in advanced pre-clinical development, IND for first ADC planned for mid-2026

Therapeutic areas: Oncology
Modalities: Bispecific monoclonal antibodyAntibody-drug conjugate
Industry: Biotech

Beyond the preview

Go deeper on Crescent Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crescent Group.

Explore the full profile